Once clinical suspicion has been established for primary biliary cholangitis (PBC), the "serologic hallmark" of the ...
The study enrolled 238 people with primary biliary cholangitis (PBC) and cholestatic pruritus, a medical term for relentless ...
Interim results from the ongoing GLISTEN trial of linerixibat, GSK's targeted inhibitor of the ileal bile acid transporter ...
On Tuesday, GSK plc (NYSE:GSK) released the headline results of the GLISTEN global phase 3 trial evaluating linerixibat in ...
GSK announces positive results from GLISTEN phase III trial of linerixibat in adults with cholestatic pruritus (relentless itch) associated with PBC: London, UK Wednesday, Novembe ...
Primary biliary cholangitis (PBC) has typically been considered a rare condition, with a pooled global estimated incidence of ...
British drugmaker GSK said on Tuesday its experimental therapy, linerixibat, met its main goal in a late-stage trial to treat ...
Drugmaker GSK said on Tuesday that its linerixibat candidate had shown "positive" Phase III results in cholestatic pruritus ...
On Friday, Gilead Sciences, Inc. (NASDAQ:GILD) revealed data from a two-and-a-half-year interim analysis from the ongoing ...
in adults with cholestatic pruritus associated with primary biliary cholangitis, a rare autoimmune liver disease. GLISTEN met its primary endpoint, with linerixibat resulting in an improvement in itch ...